NASDAQ:MDXH MDxHealth (MDXH) Stock Price, News & Analysis → Millionaire Investor makes surprising election prediction (From InvestorPlace) (Ad) Free MDXH Stock Alerts $2.88 +0.02 (+0.70%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$2.86▼$2.9350-Day Range$2.23▼$3.1452-Week Range$2.15▼$4.64Volume35,984 shsAverage Volume43,768 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$28.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get MDxHealth alerts: Email Address MDxHealth MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside883.8% Upside$28.33 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.33 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMDxHealth has only been the subject of 3 research reports in the past 90 days.Read more about MDxHealth's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of MDxHealth has been sold short.Short Interest Ratio / Days to CoverMDxHealth has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MDxHealth has recently increased by 13.69%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMDxHealth does not currently pay a dividend.Dividend GrowthMDxHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDXH. Previous Next 2.7 News and Social Media Coverage News SentimentMDxHealth has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MDxHealth this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for MDXH on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MDxHealth to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MDxHealth insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.70% of the stock of MDxHealth is held by insiders.Read more about MDxHealth's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for MDxHealth are expected to grow in the coming year, from ($1.03) to ($0.81) per share.Price to Book Value per Share RatioMDxHealth has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MDxHealth's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About MDxHealth Stock (NASDAQ:MDXH)MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.Read More MDXH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDXH Stock News HeadlinesMay 15 at 4:00 PM | globenewswire.comMdxhealth to Present at Upcoming Investor ConferencesMay 1, 2024 | globenewswire.comMDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMedApril 4, 2024 | finance.yahoo.comNotice convening the Annual General Meeting in BioPorto A/SMarch 12, 2024 | globenewswire.comMdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer OfferingMarch 11, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MDxHealth (MDXH), OrthoPediatrics (KIDS) and Karuna Therapeutics (KRTX)March 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for MDxHealth Amid Strong Q4 Performance and Positive Future OutlookMarch 6, 2024 | globenewswire.comMdxhealth Announces Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6February 21, 2024 | finance.yahoo.comMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6February 21, 2024 | globenewswire.comMDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6February 16, 2024 | globenewswire.comMdxhealth Announces Resignation of Board MemberJanuary 8, 2024 | finance.yahoo.comMDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues and Issues 2024 Revenue GuidanceDecember 18, 2023 | finance.yahoo.comMDxHealth Announces Completion of Transition to Single Listing on NasdaqNovember 15, 2023 | lse.co.ukMdxhealth Share Price (MDXH.BR)November 13, 2023 | finance.yahoo.comMDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting RightsNovember 8, 2023 | msn.comMDxHealth SA GAAP EPS of -$0.04, revenue of $19.35M beats by $1.05MNovember 8, 2023 | finance.yahoo.comMDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023November 6, 2023 | finance.yahoo.comMDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share ConsolidationOctober 25, 2023 | finance.yahoo.comMDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8October 19, 2023 | finance.yahoo.comMDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?October 10, 2023 | finanznachrichten.demdxhealth: MDxHealth Reports Preliminary Q3-2023 RevenuesOctober 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Terns Pharmaceuticals (TERN), MDxHealth S.A. Sponsored ADR (MDXH)October 4, 2023 | finanznachrichten.demdxhealth: MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders MeetingSeptember 26, 2023 | finance.yahoo.comMdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate CancerAugust 29, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for MDxHealth S.A. Sponsored ADR (MDXH)See More Headlines Receive MDXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/18/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Private households Sub-IndustryN/A Current SymbolNASDAQ:MDXH CUSIPN/A CIK1872529 Webmdxhealth.com Phone324-364-2070Fax32042597875Employees252Year FoundedN/APrice Target and Rating Average Stock Price Target$28.33 High Stock Price Target$70.00 Low Stock Price Target$7.00 Potential Upside/Downside+883.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$70.19 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book0.48Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.39 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael K. McGarrity (Age 61)CEO & Executive Director Comp: $566.5kMr. Ron Kalfus (Age 50)Chief Financial Officer Mr. Joseph Sollee (Age 59)Executive VP of Corporate Development & General Counsel Mr. John A. Bellano (Age 55)Chief Commercial Officer Ms. Miriam Reyes (Age 51)Executive Vice President of Operations Dr. Jason Poole Ph.D.Chief Scientific OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInstitutional OwnershipHood River Capital Management LLCSold 202,876 shares on 5/15/2024Ownership: 0.000%FAS Wealth Partners Inc.Bought 16,325 shares on 4/29/2024Ownership: 0.000%View All Institutional Transactions MDXH Stock Analysis - Frequently Asked Questions Should I buy or sell MDxHealth stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MDxHealth in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MDXH shares. View MDXH analyst ratings or view top-rated stocks. What is MDxHealth's stock price target for 2024? 4 analysts have issued twelve-month price objectives for MDxHealth's shares. Their MDXH share price targets range from $7.00 to $70.00. On average, they anticipate the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 883.8% from the stock's current price. View analysts price targets for MDXH or view top-rated stocks among Wall Street analysts. How have MDXH shares performed in 2024? MDxHealth's stock was trading at $3.94 on January 1st, 2024. Since then, MDXH stock has decreased by 26.9% and is now trading at $2.88. View the best growth stocks for 2024 here. When is MDxHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our MDXH earnings forecast. How were MDxHealth's earnings last quarter? MDxHealth SA (NASDAQ:MDXH) posted its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The business had revenue of $19.83 million for the quarter, compared to analyst estimates of $18.32 million. When did MDxHealth's stock split? MDxHealth's stock reverse split before market open on Friday, December 29th 2023. The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has MDxHealth issued on next quarter's earnings? MDxHealth updated its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $79.0 million-$81.0 million, compared to the consensus revenue estimate of $79.6 million. When did MDxHealth IPO? MDxHealth (MDXH) raised $45 million in an initial public offering on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share. Who are MDxHealth's major shareholders? MDxHealth's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hood River Capital Management LLC (0.00%) and FAS Wealth Partners Inc. (0.00%). View institutional ownership trends. How do I buy shares of MDxHealth? Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MDXH) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MDxHealth SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
